首页> 外文OA文献 >Production of plasminogen activator by alveolar macrophages in normal subjects and patients with interstitial lung disease.
【2h】

Production of plasminogen activator by alveolar macrophages in normal subjects and patients with interstitial lung disease.

机译:正常人和间质性肺疾病患者的肺泡巨噬细胞产生纤溶酶原激活剂。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Increased production of the serum protease plasminogen activator is associated with tissue damage. The in vitro production of plasminogen activator by alveolar macrophages obtained by bronchoalveolar lavage was studied in 22 normal subjects and 28 patients with interstitial lung disease to determine whether plasminogen activator is produced by normal alveolar macrophages and whether this is increased in patients with interstitial lung disease. Plasminogen activator activity, measured with an iodine-125 labelled fibrin release assay, was found to be dependent on time, effector cell numbers, and plasminogen concentration. Plasminogen activator production by alveolar macrophages from 14 normal non-smokers and eight normal smokers was similar and the mean value was 0.78 (SEM 0.16) urokinase (UK) units x 10(-8)/cell/hour. Alveolar macrophages from the seven patients with cryptogenic fibrosing alveolitis and six patients with histiocytosis-X produced more plasminogen activator (1.89 (0.25) and 4.54 (1.3) x 10(-8) UK units/cell/hour respectively) than macrophages from normal subjects (p less than 0.05), whereas those from 15 patients with sarcoidosis did not (1.09 (0.2) x 10(-8) UK units/cell/hour). Exposure of normal alveolar macrophages to immune complexes enhanced plasminogen activator production to 2.07 (0.27) x 10(-8) UK units/cell/hour, whereas exposure to products of activated T cells and to purified gamma interferon reduced plasminogen activator production (to 0.38 (0.11) and 0.62 (0.11) x 10(-8) UK units/cell/hour respectively). These studies show that plasminogen activator is produced by normal human alveolar macrophages and that its production is increased in patients with cryptogenic fibrosing alveolitis and histiocytosis-X.
机译:血清蛋白酶纤溶酶原激活物的产生增加与组织损伤有关。在22例正常受试者和28例间质性肺病患者中研究了通过支气管肺泡灌洗获得的肺泡巨噬细胞体外产生纤溶酶原激活物的方法,以确定纤溶酶原激活物是否由正常的肺泡巨噬细胞产生,以及在间质性肺病患者中是否增加。发现用碘125标记的纤维蛋白释放测定法测定的纤溶酶原激活物活性取决于时间,效应细胞数和纤溶酶原浓度。 14名正常非吸烟者和8名正常吸烟者的肺泡巨噬细胞产生的纤溶酶原激活剂相似,平均值为0.78(SEM 0.16)尿激酶(UK)单位x 10(-8)/细胞/小时。与正常受试者的巨噬细胞相比,来自7例隐源性纤维化性肺泡炎患者和6例组织细胞增生症-X患者的肺泡巨噬细胞产生的纤溶酶原激活剂更多(分别为1.89(0.25)和4.54(1.3)x 10(-8)UK单位/细胞/小时)。 (p小于0.05),而15例结节病患者则没有(1.09(0.2)x 10(-8)UK单位/细胞/小时)。正常肺泡巨噬细胞暴露于免疫复合物可使纤溶酶原激活物的产生增加到2.07(0.27)x 10(-8)UK单位/细胞/小时,而暴露于活化的T细胞产物和纯化的γ干扰素会降低纤溶酶原激活物的产生(至0.38) (0.11)和0.62(0.11)x 10(-8)UK单位/电池/小时)。这些研究表明,纤溶酶原激活剂是由正常人的肺泡巨噬细胞产生的,并且在隐源性纤维化性肺泡炎和组织细胞增生症-X的患者中其产生增加。

著录项

  • 作者

    Robinson, B W;

  • 作者单位
  • 年度 1988
  • 总页数
  • 原文格式 PDF
  • 正文语种 en
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号